Literature DB >> 21138939

Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction.

Willibald Hochholzer1, Tobias Reichlin, Claudia Stelzig, Kirsten Hochholzer, Julia Meissner, Tobias Breidthardt, Miriam Reiter, Bettina Duehsler, Heike Freidank, Katrin Winkler, Raphael Twerenbold, Christian Mueller.   

Abstract

AIMS: Angiogenic factors play an important role in the development of atherosclerosis and show pronounced changes during acute myocardial infarction (AMI). We analysed the impact of placental growth factor (PlGF) and its endogen opponent, soluble fms-like tyrosine kinase-1 (sFlt-1), on clinical outcome and the early diagnosis of AMI. METHODS AND
RESULTS: This multicentre study enrolled patients presenting with symptoms suggestive of AMI. The final diagnosis was adjudicated by two independent physicians. Levels of sFlt-1 and PlGF were compared with results of a standard troponin T and a novel high-sensitive troponin (hsTnT) assay. Of the 763 patients enrolled, 132 were diagnosed with AMI. Multivariable Cox regression analysis demonstrated sFlt-1 >84 ng/L [hazard ratios (HR) 2.6, 95% confidence intervals (CI) 1.2-5.4, P=0.01] and PlGF >20 ng/L (HR 3.6, 95% CI 1.3-10.4, P=0.02) as predictors for mortality during 1-year follow-up, independent from information provided by troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP). However, only sFlt-1 persisted as independent predictor for mortality when analysed together with hsTnT and NT-proBNP, and after adjusting for significant clinical parameters. For the diagnosis of AMI, the combination of troponin T and sFlt-1 improved the performance of troponin T alone and led to a negative predictive value of 98.3% already at time of presentation. However, sFlt-1 and PlGF added only limited diagnostic information when used together with hsTnT.
CONCLUSION: Only sFlt-1 but not PlGF provides overall independent prognostic information in patients presenting with symptoms suggestive of AMI. After the introduction of hsTnT in clinical routine, sFlt-1 and PlGF can only add limited diagnostic information for the detection or exclusion of AMI. CLINICAL TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov, NCT00470587.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21138939     DOI: 10.1093/eurheartj/ehq429

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  16 in total

1.  Association of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: a 4-year cohort study.

Authors:  Mehdi Rambod; Gunnar H Heine; Sarah Seiler; Elizabeth A Dominic; Kyrill S Rogacev; Rama Dwivedi; Ali Ramezani; Maria R Wing; Richard L Amdur; Danilo Fliser; Dominic S Raj
Journal:  Atherosclerosis       Date:  2014-08-12       Impact factor: 5.162

2.  Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study.

Authors:  Masaru Matsui; Shiro Uemura; Yukiji Takeda; Ken-Ichi Samejima; Takaki Matsumoto; Ayako Hasegawa; Hideo Tsushima; Ei Hoshino; Tomoya Ueda; Katsuhiko Morimoto; Keisuke Okamoto; Sadanori Okada; Kenji Onoue; Satoshi Okayama; Hiroyuki Kawata; Rika Kawakami; Naoki Maruyama; Yasuhiro Akai; Masayuki Iwano; Hideo Shiiki; Yoshihiko Saito
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

3.  Ratio between fms-like tyrosine kinase 1 and placental growth factor in children with congenital heart disease.

Authors:  Masaya Sugimoto; Hideharu Oka; Aya Kajihama; Kouichi Nakau; Seiko Kuwata; Clara Kurishima; Hiroshi Azuma
Journal:  Pediatr Cardiol       Date:  2014-11-12       Impact factor: 1.655

Review 4.  Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers.

Authors:  Michela Chianca; Giorgia Panichella; Iacopo Fabiani; Alberto Giannoni; Serena L'Abbate; Alberto Aimo; Annamaria Del Franco; Giuseppe Vergaro; Chrysanthos Grigoratos; Vincenzo Castiglione; Carlo Maria Cipolla; Antonella Fedele; Claudio Passino; Michele Emdin; Daniela Maria Cardinale
Journal:  Front Cardiovasc Med       Date:  2022-07-06

Review 5.  Clinical pharmacology of intravitreal anti-VEGF drugs.

Authors:  Stefano Fogli; Marzia Del Re; Eleonora Rofi; Chiara Posarelli; Michele Figus; Romano Danesi
Journal:  Eye (Lond)       Date:  2018-02-05       Impact factor: 3.775

Review 6.  Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review.

Authors:  Vivek Narayan; Elizabeth W Thompson; Biniyam Demissei; Jennifer E Ho; James L Januzzi; Bonnie Ky
Journal:  J Am Coll Cardiol       Date:  2020-06-02       Impact factor: 24.094

Review 7.  PlGF: a multitasking cytokine with disease-restricted activity.

Authors:  Mieke Dewerchin; Peter Carmeliet
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

8.  TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor 1.

Authors:  Jian-Wei Qi; Ting-Ting Qin; Li-Xia Xu; Kun Zhang; Gui-Li Yang; Jie Li; Huai-Yuan Xiao; Zhi-Song Zhang; Lu-Yuan Li
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

9.  No Added Value of Novel Biomarkers in the Diagnostic Assessment of Patients Suspected of Acute Coronary Syndrome.

Authors:  Judith M Poldervaart; Emma Röttger; Marieke S Dekker; Nicolaas P A Zuithoff; Peter W H M Verheggen; Evelyn A de Vrey; Thierry X Wildbergh; Arnoud W J van 't Hof; Arend Mosterd; Arno W Hoes
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

10.  Impact of Obstructive Sleep Apnea on the Levels of Placental Growth Factor (PlGF) and Their Value for Predicting Short-Term Adverse Outcomes in Patients with Acute Coronary Syndrome.

Authors:  Antonia Barcelo; Josep Miquel Bauça; Aina Yañez; Laura Fueyo; Cristina Gomez; Monica de la Peña; Javier Pierola; Alberto Rodriguez; Manuel Sanchez-de-la-Torre; Jorge Abad; Olga Mediano; Jose Amilibia; Maria Jose Masdeu; Joaquin Teran; Josep Maria Montserrat; Mercè Mayos; Alicia Sanchez-de-la-Torre; Ferran Barbé
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.